Solutions · For Regulatory Affairs

Classify the change before you book the submission date

CMC change management for EU variations. Workbench reads your change proposal against the Variations Regulation and the classification guidelines and cites each condition. Fee Calculation prices the variation in every market, and Alerts flags a rule change that touches a planned filing.

Workbench · classification

The category decides what you file

Type IB
ChangeSecond manufacturing site · Atorvastatin Ostra 20 mg
  1. Type IAImplement, then notify
  2. Type IBNotify, then wait 30 days
  3. Type IIApproval first
  4. ExtensionNew application
because of the conditions it meets
  • Non-sterile oral tablet

    Met
  • Same process and in-process controls

    Met
  • GMP certificate for oral tablets

    To confirm

Fee Calculation then prices the variation for the reference member state and each concerned member state.

The problem

The category decides everything, and it is easy to get wrong

Type IA, IB or II decides what you file, when you may implement the change and what it costs in each market. The answer sits in a long classification list where every entry has its own conditions. A change filed one category too low comes back at validation. One filed too high waits for an approval it did not need.

Built on the source

Every line traced to its source

Answers are written from the sources retrieved for the question, not from model memory. Here is a CMC answer, claim by claim.
The answer
  1. Tightening the limit is a Type IA variation in the EU. [2]

  2. Notify within 12 months of implementing it. [1]

  3. In the US it goes in the annual report. [5]

  4. The approved limit is Q = 75% at 45 min. [D1]

Where it came from
  1. [1]
    Regulation (EC) No 1234/2008Article 8 · Type IA notifications
    EUR-Lex
  2. [2]
    Variations classification guidelineChanges to finished product specifications
    EudraLex
  3. [5]
    Changes to an approved NDA or ANDASpecifications · annual report changes
    FDA Guidance
  4. [D1]
    change-control-cc-2291.pdfPage 3 · current dissolution limit
    Your document
What it searches
  • US FDA 8
  • EU & EMA 9
  • ICH & standards 6
  • National agencies 5
  • Global regulators 4
  • Terminology 4
  • HTA bodies 3
  • Clinical & literature 2
  • Your documents
How it works

From a change proposal to a priced submission

Workbench classifies the change

Workbench reads the change proposal and the approved dossier sections against each classification condition. It cites the regulation and the guideline, and marks what it could not confirm from your documents.

Fee Calculation prices it

Type IA, IB and II variations carry different fees at each agency. Fee Calculation gives the fee per market for the procedure, with the source of every fee line.

Alerts flags a rule change

Alerts matched the revised EU variations framework, which applies from 15 January 2026, to four Ostra products whose annual Type IA updates were planned under the old grouping.

In Workbench

Assess a second manufacturing site

Ostra wants Site B added for Atorvastatin 20 mg tablets, authorised through a DCP with Czechia as reference member state. Workbench reads the change proposal and the approved manufacturing section before Sara books the submission.

Workbench+ New Chat
History Atorvastatin second manufacturing site Sources
You09:14 AM

We are adding Site B as a second manufacturing site for Atorvastatin Ostra 20 mg tablets (CZ/H/0712/002/DC). Using the attached change proposal and approved manufacturing section, which variation is it and what do we still need?

change-proposal-site-b.pdfReady
Regunaut09:14 AM
  1. understanding your question…

    Atorvastatin Ostra 20 mg · CZ/H/0712/002/DC · additional manufacturing site

Warning details⌄
  • The GMP certificate for Site B is not in either document. The classification depends on it.

1. Short answer

Type IB, provided Site B holds a GMP certificate covering oral tablets and the process and controls stay as approved. Transferring the analytical methods to Site B may need its own variation.

2. Conditions checked

ConditionStatus
Non-sterile oral tabletMet [D1]
Same process and in-process controlsMet [D2]
GMP certificate for oral tabletsTo confirm: not in D1 or D2 [2]

3. Before booking the date

  • Get Site B's GMP certificate and check that its scope covers oral tablets.
  • Decide whether the analytical method transfer goes in the same submission.
  • Price the variation for the reference member state and each concerned member state.
Citations (5)⌄
Helpful? Copy PDF
Example response · Condensed for this product demonstration
Ask a follow-up question...↑
In the platform today

The jobs teams run for this

Each of these is a quick task in Workbench or a tool with a screen of its own. Picking a quick task writes the prompt for you; add your product and market, and the answer comes back with its sources.

Why Regunaut

A classification you can check line by line

Every condition cited

Each classification condition is shown with its status and the passage it comes from: the regulation, the guideline or your own document.

Gaps named, not guessed

Where a condition cannot be confirmed from what you attached, Workbench says so and names the document it needs.

The fee before the filing

Fee Calculation prices Type IA, IB and II variations per market, so the budget is known before the submission date is booked.

Related on Regunaut

Classify your next change with the sources beside it

See Workbench, Fee Calculation and Alerts on your own products and markets in a 30-minute walkthrough.